a that is find H CAPAGINE

New evidence for workforce planning

R White, J Goodchild Macmillan Cancer Support

Background

The Cancer Patient Experience Survey has shown one factor is consistently linked to good patient experience – whether people are given the name of the clinical nurse specialist (CNS) in charge of their care. Most people with cancer are given support from a CNS but still 12% in Wales¹ and 11% in England² report not having a named CNS.

In 2014 Macmillan commissioned the first UK-wide cancer nurse census.

Methodology

Inclusion criteria:

- Nurses who treat, support and manage adult cancer patients and promote health and wellbeing
- Agenda for Change band 5 to 9
- Vacant and filled posts

Excluded nurses:

- Specialists in chemotherapy, radiotherapy, palliative care or pain management
- Roles focusing on paediatrics or teenagers and young adults

The methodology was largely based on previous NCAT censuses undertaken in England³. Data was primarily collected through bespoke spreadsheets. These were sent to senior or lead cancer nurses / managers between April and June 2014. Respondents were asked to describe all hospital-based specialist adult cancer nurse posts on the 24 April 2014.

- Community care
- Non-patient facing roles
- 'As and when required' bank and agency staff

Results

The census identified the whole time equivalent (WTE) of 3,471 filled nurse posts and 124 vacant posts in the UK, a total of 3,595 WTEs. The majority (79%) of nurses were Clinical Nurse Specialists however we identified 738 WTEs of nurses with similar roles but different job titles – Figure 1.

The most common majority areas of practice align with the most common cancers; breast (19% of WTEs), colorectal (13%) and urology (12%) – Figure 2. However, there is apparent variation in nurse provision across areas of practice.

Figure 2 – Specialist adult cancer nursing workforce by majority area of practice, WTE, UK, 2014

Colorectal 13%

Urology **12%**

Lung **11%**

Haematology **10%**





There is no centrally agreed formula for determining the appropriate numbers of specialist nurses⁴. It is impractical to calculate if there is sufficient nurse provision fully taking into account the many aspects of need and service design. However, as a very crude measure, using the most recently available data at the time, we have mapped WTE onto new cancer cases (incidence in 2012) and onto the number of people living up to two years post a cancer diagnosis (two-year prevalence in 2010). This analysis showed that urology has the highest ratio; linked to a diverse case load including prostate, bladder (including in situ) and kidney cancer. The lowest ratio of cases per nurse is in brain and nervous system (incidence) and upper gastrointestinal cancer (2-year prevalence) – Figure 3.

Figure 3 – Specialist adult cancer nursing workforce ratios against incidence⁵ and two year prevalence⁶ (WTE nurse per cancer patient)



Urology

New cancer cases (incidence)

People living up to 2 years post a cancer diagnosis (prevalence)

259

166 86 147 **Breast** 140 Gynaecology 89 Malignant Dermatology 80 136 Colorectal 96 134 78 112 Head and Neck 79 109 Haematology 93 Sarcoma 110 127 85 Lung 78 59 Brain/Central Nervous System 73 103 Upper Gastrointestinal

Conculsion

Specialist cancer nurses play a critical role in cancer care, so workforce planning is essential. The higher ratio of nurses to patients is in urology, together with only 79% of urology patients reporting being given the name of a CNS²– lower than any other tumour type, and the 12% increase in prostate cancer cases over 5 years⁷ indicate that the urology workforce could benefit from review and potential redesign. This would take account of the wider healthcare system and the specific needs of men with prostate cancer across the pathway

	Upper Gastrointestinal 9%	redesign. This would take account of the wider healthcare system and the specific needs of men with prostate cancer across the pathway.
		Acknowledgements – Mouchel Management Consulting Ltd (with support from the Centre for Workforce Intelligence)
		Full research reports available here – www.macmillan.org.uk/Aboutus/Ouresearchandevaluation/Researchandevaluation/Researchandevaluationreports.aspx#DynamicJumpMenuManager_2_Anchor_2
	Acute Oncology Service 8%	For more information please contact Rachel White, rwhite@macmillan.org.uk
		June 2015
		References 1. NHS Wales, Welsh Government and Macmillan Cancer Support. Wales Cancer Patient Experience Survey National Report January 2014.
	Gynaecology 6%	 Department of Health. Cancer Patient Experience Survey 2014 National Report. NCAT Quality in Nursing. Clinical nurse specialists in cancer care: Provision, proportion and performance. A census of the cancer specialist nurse workforce in England 2011.
	Head and Neck 5%	 Trevatt P, Leary A (2010b) Commissioning the specialist cancer nursing workforce Cancer Nursing Practice. 9, 5, 23–26. Office for National Statistics. Cancer Registration Statistics, England, 2012. Personal correspondence with the biostatisticians/researchers at the Northern Ireland Cancer Registry (August 2014), personal correspondence with the Senior Statistician, Welsh Cancer Intelligence & Surveillance Unit. ISD Scotland. Cancer incidence and mortality in Scotland by site/type of cancer, sex and year of diagnosis/registration of death: 2003–2012 and personal correspondence with the Information Analyst at the Information Services Division (ISD) of NHS National Services Scotland (August 2014).
	Malignant Dermatology 5%	 National Cancer Intelligence Network. 2014. Macmillan-NCIN work plan – 20-year cancer prevalence for the period 1991–2010 by cancer type for each UK nation, the UK combined and England Strategic Clinical Networks. Data sourced and presented in collaboration with the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales, the Information Services Division Scotland and the Northern Ireland Cancer Registry. Growth in prostate cancer incidence between 2008 and 2012 based on Office of National Statistics. Cancer Registration Statistics, England, 2012, Welsh Cancer
	Brain/Central Nervous System 2% Sarcoma 1%	